Article Versions Notes

Minamiguchi K, Irizato M, Nakano R, Kunichika H, Tachiiri T, Taiji R, Tsuji Y, Yasuda S, Yoshiji H, Sho M, et al. Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Current Oncology. 2025; 32(12):694. https://doi.org/10.3390/curroncol32120694

Minamiguchi, Kiyoyuki, Mariko Irizato, Ryota Nakano, Hideki Kunichika, Tetsuya Tachiiri, Ryosuke Taiji, Yuki Tsuji, Satoshi Yasuda, Hitoshi Yoshiji, Masayuki Sho, and et al. 2025. "Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma" Current Oncology 32, no. 12: 694. https://doi.org/10.3390/curroncol32120694

Minamiguchi, K., Irizato, M., Nakano, R., Kunichika, H., Tachiiri, T., Taiji, R., Tsuji, Y., Yasuda, S., Yoshiji, H., Sho, M., & Tanaka, T. (2025). Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Current Oncology, 32(12), 694. https://doi.org/10.3390/curroncol32120694